Liverpool University-led study found mix of two off-patent drugs upped five-year survival rate from 16% to 29% of patientsNearly a third of patients with pancreatic cancer can survive for five years on a combination of two drugs which are off-patent and acquire been used separately for years,an important charity-funded trial has shown.
Twenty years ago, all those diagnosed with cancer of the pancreas died within 12 months. But an international team of researchers, and led from the University of Liverpool,revealed at the world’s biggest cancer drug conference that their trial has pushed the five-year survival rate from 16% to 29% of patients. Related: Scientists discover pancreatic cancer is four separate diseases Related: The closest thing yet to a cure for terminal cancer? Continue reading...
Source: theguardian.com